Abstract
We conducted a double-blind, placebo-controlled study to investigate the safety, pharmacokinetics, and immunological properties of interleukin-10 (IL-10) administration in healthy humans. Volunteers received a single intravenous bolus injection of recombinant human IL-10 (1, 10, or 25μg/kg) or placebo. Cytokine production in whole blood and peripheral blood mononuclear cells (PBMC) was assessed before and 3, 6, 24, and 48 hr after the injection. Peak serum concentrations of IL-10 (15±1.1, 208±20.1, and 505±22.3 ng/ml) occurred after 2–5 min for 1, 10, and 25μg/kg IL-10, respectively. The terminal-phase half-life was 3.18 hr. A transient leukocytosis (24–63% above baseline) was observed 6 hr after injection, which coincided with a dose-dependent decrease (12–24%) in neutrophil superoxide generation. There was a marked inhibition (60–95%) of endotoxin-induced IL-6 production from whole blood in each group receiving IL-10. Production of IL-8 in endotoxin-stimulated blood was reduced in the 10μg/kg group. In PBMC stimulated with phytohemagglutinin and phorbol ester, there was a decrease (72–87%) in interferon-γ (IFNγ) production 6 hr after IL-10 with a return to pre-IL-10 levels after 24 hr. This reduction was only partially associated with a decrease in the number of CD2-bearing cells. We conclude that IL-10 administration into humans is without significant side effects, and a single injection reducesex vivo production of IL-6, IL-8, and IFNγ.
Similar content being viewed by others
References
Yssel H, De Waal Malefyt R, Roncarolo M, Abrams JS, Lahesmaa R, Spits H, De Vries JE: IL-10 is produced by subsets of human CD4+ T cell clones and peripheral blood T cells. J Immunol 149:2378–2384, 1992
Viera P, De Waal Malefyt R, Dang MN, Johnson KE, Kastelein R, Fiorentino DF, De Vries JE, Roncarlo MG, Mosmann TR, Moore KW: Isolation and expression of human cytokine synthesis inhibitory factor cDNA clones: Homology to Epstein-Barr virus open reading frame BCRFI. Proc Natl Acad Sci USA 88:1172–1176, 1991
Taga K, Tosato G: IL-10 inhibits T cell proliferation and IL-2 production. J Immunol 148:1143–1148, 1992
Dinarello CA: Biologic basis for interleukin-1 in disease. Blood 87:2095–2147, 1996
de Waal Malefyt R, Abrams J, Bennett B, Figdor CG, de Vries JE: Interleukin 10 (IL-10) inhibits cytokine synthesis by human monocytes: An autoregulatory role of IL-10 produced by monocytes. J Exp Med 174:1209–1220, 1991
Cassatella MA, Meda L, Bonora S, Ceska M, Constantin G: Interleukin 10 (IL-10) inhibits the release of proinflammatory cytokines from human polymorphonuclear leukocytes. Evidence for an autocrine role of tumor necrosis factor and IL-1β in mediating the production of IL-8 triggered by lipopolysaccharide. J Exp Med 178:2207–2211, 1993
Schindler R, Dinarello CA: Ultrafiltration to remove endotoxins and other cytokine-inducing materials from tissue culture media and parenteral fluids. Biotechniques 8:408–413, 1990
Chernoff AE, Granowitz EV, Shapiro L, Vannier E, Lonnemann G, Angel JB, Kennedy JS, Rabson AR, Wolff SM, Dinarello CA: A randomized, controlled trial of interleukin-10 in humans: Inhibition of inflammatory cytokines and immune responses. J Immunol 154:5492–5499, 1995
Klempner MS, Dinarello CA, Henderson WR, Gallin JI: Stimulation of neutrophil oxygen-dependent metabolism by human leukocyte pyrogen. J Clin Invest 64:996–1002, 1979
Cannon J, Van der Meer J, DK, Endres S, Lonnemann G, Burke J, Dinarello C: Interleukin-1β in human plasma: Optimization of blood collection, plasma extraction, and radioimmunoassay methods. Lymphokine Res 7:457–467, 1988
van der Meer JWM, Endres S, Lonnemann G, Cannon JG, Ikejima T, Okusawa S, Gelfand JA, Dinarello CA: Concentrations of immunoreactive human tumor necrosis factor-α produced by human mononuclear cellsin vitro. J Leukoc Biol 43:216–223, 1988
Schindler R, Mancilla J, Endres S, Ghorbani R, Clark SC, Dinarello CA: Correlations and interactions in the production of interleukin-6 (IL-6), IL-1, and tumor necrosis factor (TNF) in human blood mononuclear cells: IL-6 suppresses IL-1 and TNF. Blood 75:40–47, 1990
Porat R, Poutsiaka DD, Miller LC, Granowitz EV, Dinarello CA: Interleukin-1 (IL-1) receptor blockade reduces endotoxin andBorrelia burgdorferi-stimulated IL-8 synthesis in human mononuclear cells. FASEB J 6:2482–2486, 1992
Shapiro L, Clark BD, Orencole SF, Poutsiaka DD, Granowitz EV, Dinarello CA: Detection of tumor necrosis factor soluble receptor p55 in blood samples from healthy and endotoxemic humans. J Infect Dis 167:1344–1350, 1993
Poutsiaka DD, Clark BD, Vannier E, Dinarello CA: Production of interleukin-1 receptor antagonist and interleukin-1β by peripheral blood mononuclear cells is differentially regulated. Blood 78: 1275–1281, 1991
Bocci V: Interleukins: Clinical pharmacokinetics and practical implications. Clin Pharmacokinet 21:274–284, 1991
Rousset F, Garcia E, Defrance T, Peronne C, Vezzio N, Hsu D, Kastelein R, Moore KW, Banchereau J: Interleukin 10 is a potent growth and differentiation factor for activated human B lymphocytes. Proc Natl Acad Sci USA 89:1890–1893, 1992
Zielen S, Bauscher P, Hofmann D, Meuer SC: Interleukin 10 and immune restoration in common variable immunodeficiency [letter]. Lancet 342:750–751, 1993
Mulligan MS, Jones ML, Vaporciyan AA, Howard MC, Ward PA: Protective effects of IL-4 and IL-10 against immune complex-induced lung injury. J Immunol 151:5666–5674, 1993
Helle M, Brakenhoff JP, De GER and Aarden LA: Interleukin 6 is involved in interleukin 1-induced activities. Eur J Immunol 18: 957–959, 1988
Hirano T, Taga T, Nakano N, Yasukawa K, Kashiwamura S, Shimizu K, Nakajima K, Pyun KH, Kishimoto T: Purification to homogeneity and characterization of human B cell differentiation factor (BCDF or BSFp-2). Proc Natl Acad Sci USA 82:5490–5494, 1985
Gauldie J, Richards C, Harnish D, Lansdorp P, Baumann H: Interferonβ2/B-cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells. Proc Natl Acad Sci USA 84:7251–7255, 1987
Kawano M, Hirano T, Matsuda T, Taga T, Horii Y, Iwato K, Asaoku H, Tang B, Tanabe O, Tanaka H, Kuramoto A, Kishimoto T: Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature 332:83–85, 1988
Nordan RP, Potter M: A macrophage-derived factor required by plasmacytomas for survival and proliferation in vitro. Science 233:566–569, 1986
Houssiau FA, Devogelaer J-P, Van Damme J, De Deuxchaisnes CN, Van Snick J: Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides. Arth Rheum 31:784–788, 1988
Hirano T, Taga T, Kiyoshi Y, Nakajima K, Nakano N, Takatsuki F, Shimizu M, Murashima A, Tsunasawa S, Sakiyama F, Kishimoto T: Human B-cell differentiation factor defined by an antipeptide antibody and its possible role in autoantibody production. Proc Natl Acad Sci USA 84:228–231, 1987
Yoshizaki K, Matsuda T, Nishimoto N, Kuritani T, Taeho L, Aozasa K, Nakahata T, Kawai H, Tagoh H, Komori T, Kishimoto S, Hirano T, Kishimoto T: Pathological significance of interleukin 6 (IL-6/BSF2) in Castelmans' disease. Blood 74:1360–1367, 1989
Beck JT, Hsu S, Wijdenes J, Bataille R, Klein B, Vesole D, Hayden K, Jagannath S, Barlogie B: Brief report: Alleviation of systemic manifestations of Castelman's disease by monoclonal anti-interleukin-6 antibody. N Engl J Med 330:602–605, 1994
Elias JA, Schreiber AD, Gustilo K, Chien P, Rossman MD, Lammie PJ, Daniele RP: Differential interleukin 1 elaboration by unfractionated and density fractionated human alveolar macrophages and blood monocytes: Relationship to cell maturity. J Immunol 135:3198–3204, 1985
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Fuchs, A.C., Granowitz, E.V., Shapiro, L. et al. Clinical, hematologic, and immunologic effects of interleukin-10 in humans. J Clin Immunol 16, 291–303 (1996). https://doi.org/10.1007/BF01541395
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01541395